IP Library Granted Patent US 12,054,510
Granted Patent B2
US 12,054,510 · App. 17/833,780 · Granted Aug 6, 2024

2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds

Inventors: Hugh Griffith (Edinburgh, GB); Christopher McGuigan (Cardiff, GB); Valentina Ferrari (Cardiff, GB); Michaela Serpi (Cardiff, GB); Carmen Jimenez Antunez (Cardiff, GB)
Assignee: NuCana plc
C07H19/20C07H19/173
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,054,510
App. No.
17/833,780
Granted
Aug 6, 2024
Kind
B2
Abstract

The present invention relates to chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours in Homo sapiens . The compounds are derivatives of cordycepin (3′-deoxyadenosine).

Claims (9)

1. A compound which is 3′-Deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition, comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , in an oral dosage form.

4. The pharmaceutical composition of claim 2 , in a liquid dosage form.

5. The pharmaceutical composition of claim 4 , in an aqueous solution of or suspension.

6. The pharmaceutical composition of claim 5 , in an intravenous formulation.

7. The pharmaceutical composition of claim 5 , in a parenteral formulation.

8. The pharmaceutical composition of claim 2 , that contains from 50 mg to 700 mg of the compound.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2024
From: GRIFFITH, HUGH; MCGUIGAN, CHRISTOPHER
To: NUCANA BIOMED LIMITED
Reel/Frame 067326/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2024
From: GRIFFITH, HUGH; FERRARI, VALENTINA; SERPI, MICHAELA; ANTUNEZ, CARMEN JIMENEZ
To: NUCANA BIOMED LIMITED
Reel/Frame 067326/0123 →
CHANGE OF NAME Recorded May 6, 2024
From: NUCANA BIOMED LIMITED
To: NUCANA PLC
Reel/Frame 067326/0129 →
Priority Claims (2)
GB 1421211 · Nov 28, 2014 · national
GB 1519316 · Nov 2, 2015 · national
Continuity (3)
Continuation 16782952 · Feb 5, 2020
Continuation 15518527
Related Publication 20220306675A1 · Sep 29, 2022